Sudo secures additional funds to advance TYK2 inhibitors to clinic
Sudo Biosciences secured $30m in second round of Series B funding to further the development of TYK2 inhibitors into the clinic.
Sudo Biosciences secured $30m in second round of Series B funding to further the development of TYK2 inhibitors into the clinic.
What's Your Reaction?
